Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Topical Ocular BL1332 low dose
Ocular BL1332 low dose · 1 trial · 1 indication
Ocular pain intensity assessed using numeric pain rating scale 0 to 10, with 10 being the worst pain
| Arm | Type | Description |
|---|---|---|
| Topical Ocular BL1332 low dose | EXPERIMENTAL | BL1332 low dose ocular drop used 5x daily |
| Topical Ocular BL1332 high dose | EXPERIMENTAL | BL1332 high dose ocular drop used 5x daily |
| BL1332 ophthalmic vehicle | PLACEBO_COMPARATOR | BL1332 vehicle ocular drop used 5x daily |
| Name | Type | Description |
|---|---|---|
| Topical Ocular BL1332 low dose | DRUG | Administered 5 times a day |
| Topical Ocular BL1332 high dose | DRUG | Administered 5 times a day |
| BL1332 Vehicle ophthalmic vehicle | DRUG | Administered 5 times a day |
Inclusion Criteria: 1. Male or female 18 to 58 years of age, inclusive. 2. Scheduled to undergo PRK surgery and considered to be a good candidate per the Investigator's discretion. 3. Provide written informed consent (signed and dated informed consent form \[ICF\]) using the Institutional Review Bo...
Ocular BL1332 low dose is an investigational small molecule being developed for the management of postoperative ocular pain, specifically following photorefractive keratectomy. It is a topical ophthalmic formulation currently in Phase 2 clinical development.
The specific molecular target of Ocular BL1332 low dose has not been disclosed. It is a small molecule administered topically to the eye, intended to manage postoperative ocular pain, but its mechanism of action is not publicly detailed.
Ocular BL1332 low dose is being developed by Bausch + Lomb Corporation, a company publicly traded under the ticker symbol BLCO. The company is conducting clinical trials to evaluate the drug for postoperative ocular pain.
Ocular BL1332 low dose is in Phase 2 clinical development. It is an investigational drug, not yet approved by regulatory authorities, and is being studied for the management of postoperative ocular pain following photorefractive keratectomy.
Ocular BL1332 low dose is being evaluated in a Phase 2 clinical trial registered as NCT07412496. This randomized, double-blind, placebo-controlled study is assessing the drug for postoperative ocular pain following photorefractive keratectomy, with an estimated enrollment of 123 participants.
Yes, Ocular BL1332 low dose is also known as Topical Ocular BL1332 low dose. Both names refer to the same investigational drug being developed by Bausch + Lomb Corporation for postoperative ocular pain.